Bioavailability of 2 granule formulations (enteric-coated and uncoated) of ridaforolimus versus an enteric-coated tablet formulation in male volunteers

Trial Profile

Bioavailability of 2 granule formulations (enteric-coated and uncoated) of ridaforolimus versus an enteric-coated tablet formulation in male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2013

At a glance

  • Drugs Ridaforolimus (Primary)
  • Indications Soft tissue sarcoma
  • Focus Pharmacokinetics
  • Sponsors Celerion; Merck & Co
  • Most Recent Events

    • 20 Mar 2013 New trial record
    • 09 Mar 2013 Results presented at the 62nd Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top